Photo by nci from unsplash
Selective targeting of N‐Myc‐driven Sonic hedgehog (SHH) medulloblastoma has been a challenge for many years and, despite decades of research, few targeted therapy opportunities exist. Recently, Kuzuoglu‐Ozturk et al. characterized… Click to show full abstract
Selective targeting of N‐Myc‐driven Sonic hedgehog (SHH) medulloblastoma has been a challenge for many years and, despite decades of research, few targeted therapy opportunities exist. Recently, Kuzuoglu‐Ozturk et al. characterized the translatome of N‐Myc‐driven medulloblastoma as a promising therapeutic target. The study showed that N‐Myc controls a subset of members of the protein folding machinery that could be inhibited pharmacologically and validated a subset of Hsp70 functions as required for medulloblastoma progression in vitro and in vivo.
Journal Title: Molecular Oncology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!